glucose, (beta-d)-isomer has been researched along with 3-hydroxybutyric acid in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Masuzawa, Y; Ojima-Uchiyama, A; Sugiura, T; Waku, K | 1 |
| Burton, JD; Danehower, DA; Finney, MM | 1 |
| Cerone, SI; García, MC; Sansinanea, AS | 1 |
| Cullen, MJ; Devenny, JJ; Godonis, HE; Harvey, SJ; Pelleymounter, MA; Rooney, S | 1 |
| Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
| Ferrannini, E; Mark, M; Mayoux, E | 1 |
| Dandona, P; Hansen, L; Henry, RR; Mudaliar, S; Pettus, J; Xu, J | 1 |
| Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF | 1 |
| Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS | 1 |
| Fukuhara, A; Nishitani, S; Okuno, Y; Otsuki, M; Shimomura, I; Shin, J | 1 |
| Cha, BS; Cho, JW; Kang, ES; Kim, JH; Kim, SH; Kim, SR; Lee, BW; Lee, M; Lee, YH | 1 |
| Fukushima, A; Furihata, T; Kakutani, N; Katayama, T; Kinugawa, S; Maekawa, S; Matsumoto, J; Nakano, I; Nambu, H; Obata, Y; Saito, A; Shirakawa, R; Takada, S; Yamanashi, K; Yokota, T | 1 |
| Cao, Y; Dong, P; Jia, L; Jiang, M; Li, C; Liang, Q; Shi, H; Song, T; Wang, P | 1 |
| Achenbach, S; Bosch, A; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Pietschner, R; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
4 trial(s) available for glucose, (beta-d)-isomer and 3-hydroxybutyric acid
| Article | Year |
|---|---|
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Topics: 3-Hydroxybutyric Acid; Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects | 2017 |
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Benzhydryl Compounds; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Male; Pilot Projects; Young Adult | 2017 |
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Topics: 3-Hydroxybutyric Acid; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Up-Regulation; Vascular Stiffness | 2021 |
10 other study(ies) available for glucose, (beta-d)-isomer and 3-hydroxybutyric acid
| Article | Year |
|---|---|
Augmented production of platelet-activating factor in human polymorphonuclear leukocytes by ketone bodies.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Calcimycin; Dimethyl Sulfoxide; Humans; Hydroxybutyrates; In Vitro Techniques; Kinetics; Neutrophils; Platelet Activating Factor; Tetradecanoylphorbol Acetate; Zymosan | 1989 |
Gas chromatographic method for the analysis of allelopathic natural products in rye (Secale cereale L.).
Topics: 3-Hydroxybutyric Acid; Benzoxazines; Benzoxazoles; Chromatography, Gas; Gas Chromatography-Mass Spectrometry; Glucosides; Herbicides; Lactates; Oxazines; Secale | 2005 |
Effects of beta-hydroxybutyric acid on bovine milk leukocytes function in vitro.
Topics: 3-Hydroxybutyric Acid; Animals; Cattle; Female; Hydrogen Peroxide; Ketone Bodies; Ketosis; Leukocytes; Macrophages; Milk; Neutrophils; Nitroblue Tetrazolium; Phagocytosis; Tetradecanoylphorbol Acetate; Zymosan | 2007 |
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Topics: 3-Hydroxybutyric Acid; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Blood Glucose; Caloric Restriction; Diet; Dose-Response Relationship, Drug; Drinking; Energy Intake; Glucosides; Hyperphagia; Insulin; Male; Obesity; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Respiration; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2012 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Ketosis; Middle Aged; Young Adult | 2018 |
Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes.
Topics: 3-Hydroxybutyric Acid; Adiponectin; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Gene Expression Profiling; Glucosides; Metabolome; Metabolomics; Mice; Mice, Inbred NOD; Microarray Analysis; Sodium-Glucose Transporter 2 Inhibitors; Transcriptome; Up-Regulation | 2018 |
Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk.
Topics: 3-Hydroxybutyric Acid; Animals; Benzhydryl Compounds; Colon; Endoplasmic Reticulum Stress; Glucosides; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypoglycemic Agents; Insulin; Intestinal Mucosa; Ketone Bodies; Kidney; Kidney Tubules, Proximal; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Monocarboxylic Acid Transporters; Oxo-Acid-Lyases; Random Allocation; Rats; RNA, Messenger; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Disease Models, Animal; Fatty Acids; Glucosides; Heart Failure; Insulin; Male; Mice; Mice, Inbred C57BL; Mitochondria; Muscle Strength; Muscle, Skeletal; Oxidation-Reduction; Oxidative Phosphorylation; Physical Conditioning, Animal; Physical Endurance; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Salidroside simultaneously reduces de novo lipogenesis and cholesterol biosynthesis to attenuate atherosclerosis in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Glucose; Glucosides; Glycogen; Hypercholesterolemia; Lipidomics; Lipogenesis; Liver; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Phenols; Proton Magnetic Resonance Spectroscopy | 2021 |